Industry Veteran Will Lead HST5040 and Future Rare Disease Clinical Programs HemoShear Therapeutics, Inc., a privately held biotechnology company developing drugs for rare metabolic disorders, has appointed Patrick Horn, MD, PhD, as Chief Medical Officer, effective January 1, 2022. Dr. Horn will lead the company’s growing clinical operations, clinical development, regulatory affairs, medical affairs, biometrics …

The coalition will compete for up to $100 million to supercharge the economy of Central Virginia The coalition of public and private organizations in support of creating an advanced pharmaceutical cluster in Central Virginia was named by the Economic Development Administration (EDA) as a finalist in the $1 billion Build Back Better Regional Challenge.  The …

RIVANNA®, developers of world-first, imaging-based medical solutions, announced they have entered into a partnership with BOMImed, a recognized manufacturer of anesthesia and critical care related consumables to represent and distribute the Accuro® portfolio of products in Canada. BOMImed is a choice distribution partner for RIVANNA as its focus is within the fields of anesthesia and critical …

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it is accepting letters of intent (LOI) for Grant Round 13 to fund the development and commercialization of life science projects that address major unmet needs for improving human health and advance Virginia’s economy. “When you combine world class research with …

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment of Cary J. Claiborne as Chief Operating Officer. Mr. Claiborne will continue to serve on the Board of Directors. In his new role, Mr. Claiborne will be responsible for overseeing …

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is proud to announce the launch of the NIH Technology Accelerator Challenge for Maternal Health (NTAC: Maternal Health) in conjunction with the White House Maternal Health Day of Action.  NTAC: Maternal Health is offering up to $1,000,000 in cash prizes to reward the development of low-cost, point-of-care molecular, cellular, and/or metabolic sensing …